Nuo Therapeutics (OTCPK:AURX) - Stock Price, News & Analysis

AURX Stock Overview

A regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. More details

AURX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 39.5% per year over past 5 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the US market

Does not have meaningful revenue ($1M)

+ 2 more risks

Nuo Therapeutics, Inc. Competitors

Kronos Bio

NasdaqGS:KRON

US$51.9m

BioXcel Therapeutics

NasdaqCM:BTAI

US$24.0m

Spruce Biosciences

NasdaqCM:SPRB

US$20.2m

Tonix Pharmaceuticals Holding

NasdaqCM:TNXP

US$33.9m

Price History & Performance

Summary of all time highs, changes and price drops for Nuo Therapeutics
Historical stock prices
Current Share Price	US$1.09
52 Week High	US$1.27
52 Week Low	US$0.25
Beta	-740.14
11 Month Change	75.35%
3 Month Change	32.12%
1 Year Change	119.54%
33 Year Change	n/a
5 Year Change	1,262.50%
Change since IPO	-45.50%

Recent updates

Shareholder Returns

	AURX	US Biotechs	US Market
7D	50.1%	-3.7%	0.3%
1Y	119.5%	15.2%	31.1%

Return vs Industry: AURX exceeded the US Biotechs industry which returned 14.6% over the past year.

Return vs Market: AURX exceeded the US Market which returned 30.3% over the past year.

Price Volatility

Is AURX's price volatile compared to industry and market?
AURX volatility
AURX Average Weekly Movement	26.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: AURX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: AURX's weekly volatility has decreased from 34% to 26% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1998	9	David Jorden	www.nuot.com

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds.

Nuo Therapeutics, Inc. Fundamentals Summary

How do Nuo Therapeutics's earnings and revenue compare to its market cap?
AURX fundamental statistics
Market cap	US$54.05m
Earnings (TTM)	-US$2.48m
Revenue (TTM)	US$1.17m

43.5x

P/S Ratio

-20.5x

P/E Ratio

Is AURX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AURX income statement (TTM)
Revenue	US$1.17m
Cost of Revenue	US$257.80k
Gross Profit	US$909.52k
Other Expenses	US$3.39m
Earnings	-US$2.48m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.053
Gross Margin	77.92%
Net Profit Margin	-212.47%
Debt/Equity Ratio	0%

How did AURX perform over the long term?

See historical performance and comparison

Nuo Therapeutics OTCPK:AURX Stock Report